The cannabis sector reached an important milestone recently. While attention centered on SpaceX and its public offering, significant developments also occurred in the marijuana space.

Trulieve Cannabis (NYSE: TRLV) has commenced trading on the New York Stock Exchange using the ticker TRLV. This event stands out for the sector because it marks the initial listing of a domestically based cannabis firm on a prominent U.S. exchange. Previously, federal restrictions forced American cannabis companies onto over-the-counter platforms with limited investor access. That situation has now changed.

Should investors consider Trulieve shares at present?

Image source: Getty Images.

Trulieve holds a strong position in the sector

Trulieve ranks among the largest multi-state operators nationwide, operating more than 200 sites. The firm maintains particular strength in Florida, where it recently launched its 170th location. Its leading role in the market, combined with a medical marijuana focus, has supported solid expansion amid rising interest in cannabis for therapeutic uses such as pain management.

Over the past twelve months, Trulieve recorded roughly 1.2 billion dollars in revenue alongside an operating profit of 149 million dollars. The business ranks among the most robust financially in its field. It stands ready to pursue growth in both medical and recreational segments going forward. Free cash flow reached 224 million dollars across the last four quarters.

Long-term investors may find Trulieve attractive currently

Trulieve shares have risen 12 percent this year. With a market capitalization below 2 billion dollars, the company remains relatively modest in size even as a key participant in an expanding field. Projections from Grand View Research indicate the U.S. cannabis market could exceed 76 billion dollars by 2030, reflecting an 11.5 percent compounded annual growth rate. Realization depends on further legalization progress, yet the figures highlight the scale of potential opportunity.

Growth-focused investors comfortable with the uncertainties of cannabis equities may view Trulieve as a worthwhile choice. Its scale, market leadership, and healthy balance sheet position it among the more stable options in the industry.